Overview of Xero

Property	Description
Active Ingredient	Dexibuprofen
Form	Tablet (Oral)
Pharmacological Class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common General Purpose	Symptomatic relief of pain, inflammation, and fever
Origin	Synthetic (S-enantiomer)

What Type of Medicine is Xero and What Does it Contain?

Xero is a medication classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), with the active substance being Dexibuprofen. This is a synthetic, single-ingredient product designed for oral administration in the form of a tablet. The classification confirms Xero belongs to the group of medicines that modify the body's inflammatory response and manage pain, a role established for NSAIDs.

How is Dexibuprofen Different from Standard Ibuprofen?

The active ingredient, Dexibuprofen, is specifically defined as the isolated, pharmacologically active isomer (the S-enantiomer) of the more widely known drug, Ibuprofen. Standard Ibuprofen is a racemic mixture containing both the active and an inactive molecular structure. Dexibuprofen is thereby an enantiomerically pure derivative of the arylpropionic acid structure, focusing on the component responsible for the therapeutic effects. In this composition, the S-enantiomer is responsible for the principal anti-inflammatory activity.

What is the General Purpose of Xero, and in What Form Does it Come?

The general therapeutic purpose of Xero is to provide comprehensive symptomatic relief for discomfort, exhibiting three core effects: an analgesic (pain-relieving) effect, an anti-inflammatory effect to reduce swelling, and an antipyretic (fever-reducing) effect. Xero achieves its effects by acting as a targeted inhibitor of the Cyclooxygenase (COX) enzyme, thereby limiting the production of prostaglandins, which are the chemical messengers that trigger these symptoms. The oral tablet formulation ensures the systematic absorption of the active ingredient into the bloodstream.

What side effects are possible with Xero?

Possible Side Effects and Safety Information for Xero

Xero is associated with a spectrum of officially documented adverse reactions, classified by system-organ class. These reactions range in frequency from Very Common (ge 1/10) to Rare (< 1/1,000). The most common adverse reactions reported often involve gastrointestinal issues, fatigue, and headache.

Serious Adverse Reactions and Key Safety Restrictions

Regulatory sources highlight the risk of several Serious Adverse Reactions (SARs), which require immediate medical attention. These include Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), Hepatotoxicity (severe liver injury), Aplastic Anemia, and serious hypersensitivity reactions like anaphylaxis. The risk of serious skin reactions is often documented as being highest during the initial weeks of treatment.

Population-Specific Considerations and Monitoring

The safety profile includes restrictions for certain patient populations. Xero is generally contraindicated during pregnancy due to potential reproductive toxicity. Patients with pre-existing hepatic impairment must use the drug with caution, and lower initial doses may be necessary due to reduced clearance. Safety and efficacy have not been established in the pediatric population (under 18 years).

To manage known risks, official safety labels recommend specific monitoring. This includes periodic assessment of liver function tests (LFTs) and hematological monitoring (e.g., complete blood count), particularly when initiating therapy. The drug must be discontinued immediately if signs of a severe skin rash, jaundice, or other serious hypersensitivity reactions occur. Concurrent use with potent CYP450 inhibitors is restricted due to the potential for increased drug exposure and toxicity.

Overdose and Emergency Response

The regulatory profile for Xero, an NSAID, defines overdose based on documented effects on the gastrointestinal (GI) and central nervous systems (CNS). Early manifestations may include nausea, vomiting, abdominal pain, dizziness, and drowsiness. More severe presentations involve acute CNS disturbances such as confusion, convulsions (seizures), unsteadiness, or stupor progressing to coma. Sensory changes like tinnitus (ringing in the ears) and blurred vision are also documented.

Documented Critical Outcomes

Severe, life-threatening outcomes listed in official prescribing information include significant gastrointestinal bleeding, ulceration, and perforation. Cardiac complications such as low blood pressure (shock) and irregular heart rhythms may occur. Other critical events involve acute kidney failure, metabolic acidosis, and respiratory depression.

When to Seek Immediate Medical Help

If overdose is suspected, seek immediate medical attention. Authorities explicitly mandate contacting emergency services immediately if life-threatening symptoms, such as difficulty breathing, severe bleeding, or loss of consciousness, are present.

Management is strictly symptomatic and supportive, as no specific antidote is described in the regulatory literature. Procedures may involve activated charcoal administration, monitoring of vital signs and ECG, and supportive respiratory or circulatory assistance. The regulatory profile notes that elderly patients and those with pre-existing impaired renal function are at greater risk for serious outcomes.

Therapeutic Uses of Xero

Xero (Dexibuprofen) may be part of symptomatic management across key therapeutic domains, commonly used for managing pain, inflammation, and fever. It is generally applied in scenarios where symptoms create noticeable interference with daily stability. The therapeutic role of the medication is aligned with domains involving significant symptom expression, confirming its use for acute and chronic symptomatic burdens.

This medication is relevant in conditions characterized by periods of heightened symptoms associated with Osteoarthritis and Rheumatoid Arthritis. It is relevant for easing symptoms related to inflammatory or irritative states, including joint pain, painful swelling, and stiffness. Xero is also applied in addressing sudden, short-term symptomatic episodes, including common headaches, acute dental pain, and the discomfort of primary Dysmenorrhea (menstrual cramps). This support contributes to improved comfort during symptomatic periods and assists with maintaining functional stability.

“It is commonly used across conditions presenting with acute episodes, offering symptomatic relief that helps patients cope more steadily with difficult, self-limiting episodes.”

Xero is commonly used to help with the symptoms associated with: chronic inflammatory conditions, acute pain states, musculoskeletal disorders, dental pain, headache, and painful menstruation.

Quick Fact: Relief for Joint Pain, Swelling, and Fever

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Xero (Dexibuprofen)

Official regulatory documents define strict criteria for using Xero, an NSAID. Use is generally established for adults (18 years and older) under standard labeled conditions.

Populations for Whom Use is Contraindicated

Absolute prohibition applies to patients with documented hypersensitivity to any NSAID, a history of NSAID-induced asthma or rhinitis, or a history of gastrointestinal bleeding or perforation.

Organ Failure: The medicine is formally contraindicated in patients with severe heart failure (NYHA Class IV), severe renal dysfunction (GFR < 30 mL/min), or severely impaired hepatic function.
Bleeding Risk: Patients with active bleeding (e.g., cerebrovascular haemorrhage) or coagulation disorders must not use the medicine.
Pregnancy: Use is contraindicated from the beginning of the third trimester of pregnancy.

Restricted and Age-Related Eligibility

Children and adolescents under 18 years of age are generally not recommended for use because safety and efficacy have not been established.

Older adults are eligible but face an increased risk of adverse reactions, particularly GI and renal complications, and therefore require use at the lowest effective dose.

Use is not recommended in women who are attempting to conceive. During the first and second trimesters of pregnancy, use is generally not recommended unless strictly necessary. Patients with mild-to-moderate organ function impairment or specific conditions like uncontrolled hypertension require caution and monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Xero’s official regulatory profile, consistent with its classification as a Non-Steroidal Anti-Inflammatory Drug (NSAID), mandates several key restrictions and documented interaction patterns.

The combination of Xero with other NSAIDs, including COX-2 selective inhibitors or other ibuprofen-containing products, is strictly advised against due to a significant, additive risk of gastrointestinal ulceration and hemorrhage. Co-administration is also contraindicated in the immediate peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery.

Several substances enhance the risk of bleeding or toxicity. Xero enhances the effect of anticoagulants such as warfarin, and increases the potential for gastrointestinal adverse events when taken concurrently with oral corticosteroids, antiplatelet agents, or SSRIs. Furthermore, Xero reduces the renal clearance of both Lithium and high-dose Methotrexate, which may lead to dangerously increased plasma concentrations of these medicines.

The medicine may also reduce the therapeutic efficacy of Diuretics and Antihypertensives (e.g., ACE Inhibitors or ARBs). This combination increases the risk of renal function deterioration, a consideration that is heightened in elderly patients and those with existing renal impairment.

A specific timing requirement applies to low-dose Aspirin used for heart protection; it should be taken at least two hours before Xero to avoid interference with its antiplatelet effect. Alcohol intake also significantly exacerbates the risk of gastrointestinal bleeding.

Mechanism of Action

The Mechanism of Action of Dexibuprofen

Xero's active component, Dexibuprofen (the S-enantiomer), is a reversible, non-selective competitive inhibitor of the Cyclooxygenase (COX-1 and COX-2) isoenzymes. The drug binds directly to the active site of these enzymes, thereby preventing the metabolic conversion of Arachidonic Acid into downstream prostanoids, including Prostaglandins ( PGE2).

This molecular blockade results in the suppression of PGE2 biosynthesis, which are key local mediators responsible for sensitizing peripheral pain receptors and increasing vascular permeability. This effect modulates a humoral signaling pathway, attenuating the signaling output that drives tissue-level responses.

The drug exerts a dual physiological effect: a peripheral reduction in nociceptor sensitization and a central regulatory effect within the hypothalamus. The centrally reduced PGE2 signaling facilitates the restoration of the hypothalamic temperature set-point, while peripheral suppression contributes to a decrease in peripheral nociceptor excitability, resulting in the precise modulation of these related homeostatic systems.

Dosage and Administration Information

How to Use Xero

Xero, which contains the active substance Dexibuprofen, is administered orally, available in film-coated tablets in strengths including 200 mg, 300 mg, and 400 mg. The overall strategy for its use is based on employing the lowest effective dose for the shortest duration necessary to control symptoms.

Standard Dosing and Frequency

The standard daily intake for adults typically ranges from 600 mg to 900 mg, divided into individual doses. For acute conditions or exacerbations of chronic conditions, the daily intake may be temporarily increased, but the total dose must not exceed 1200 mg per day. A single dose should not exceed 400 mg. The medication is generally taken up to three times per day, with an interval of at least 4 hours between successive doses.

Administration Timing and Adjustments

The tablet may be taken with or without a meal. It is often recommended that the medicine be taken preferably with food to help mitigate the potential for gastrointestinal irritation, particularly during chronic administration. For individuals with mild to moderate renal or hepatic impairment, a reduced initial dosage and close monitoring are used. Similarly, older adults (aged 65 years and over) should initiate therapy at the lower end of the recommended dosage range.

Regarding the tablet form, the score line present on some strengths is intended only to facilitate breaking the tablet for easier swallowing, and is not designed to divide the tablet into two equal, fractional doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xero

Evidence for Musculoskeletal and Chronic Inflammatory Pain

Research has explored the use of Xero (Dexibuprofen) in conditions involving periods of heightened symptoms, such as osteoarthritis and rheumatoid arthritis. Studies conducted during periods of increased symptom activity include short-term, double-blind Randomized Controlled Trials (RCTs) and controlled comparative trials. These research efforts primarily examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

For osteoarthritis, studies monitored changes in patient-reported outcomes describing perceived discomfort, along with how functional indexes like the WOMAC Osteoarthritis Index evolved over the study period. Findings describe patterns observed in the studies related to measured changes in pain intensity and physical function, often over relatively short intervals. Follow-up durations were limited, meaning there is limited information for long-term outcomes and the maintenance of the observed symptomatic changes.

Evidence for Acute Pain States

Xero was evaluated in research exploring how symptoms change over time across several acute and disruptive episodes, including pain following dental surgery, general acute pain (like headache), and primary dysmenorrhea (menstrual pain). The research scenarios used in these evaluations were typically highly controlled, single-dose, placebo-controlled RCTs, or comparative studies.

In the case of acute postoperative pain, studies focused on episodes where symptoms become more noticeable, measuring the time taken for a change in symptom intensity to be observed and the proportion of participants reporting specific levels of changes in pain measures. Reported outcomes describe patterns related to the onset of measured symptomatic change in highly controlled, acute pain settings. However, results apply only to the specific acute pain models studied, and there is limited information for long-term outcomes for continuous use in acute pain management.

Long-Term Research and Maintenance of Effect

The majority of published clinical trials examining Xero are designed to assess short-term symptomatic change or acute-dose effects. Research exploring the effects of using the medication over periods of many months or for maintenance therapy is not extensively characterized. Therefore, long-term effects are not fully established. Data are still emerging regarding the sustainability of the response, specifically the extent to which any recorded change in symptoms persists over extended periods of time.

Research Gaps and Areas of Uncertainty

The research evidence provides context but not individual predictions, and it highlights what is known and what is still uncertain. Key limitations documented in the scientific literature include: limited information for long-term outcomes, insufficient data for certain patient groups, and evidence quality that varies across studies. In some early trials, sample sizes were modest, which limits the confidence in applying the observed patterns related to symptom changes to larger, more varied populations.

Key Studies & References

NICE Guideline on Osteoarthritis: Care and Management in Adults

Frequently Asked Questions (FAQ)

Common questions about Xero (FAQ)

Q: Is Xero a controlled substance?

Xero is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its active ingredient, Dexibuprofen, is designated as a non-narcotic medicine and is therefore not designated as a controlled substance under major drug schedules.

Q: What should I expect the effects of Xero to feel like?

The medicine is intended to provide symptomatic relief by reducing discomfort, lowering fever, and easing inflammation. While these are the intended effects, official product information also describes potential common temporary effects such as headache or gastrointestinal issues.

Q: Does Xero cause tiredness or drowsiness?

Official product information, which details the drug's safety profile, describes that the medicine may cause adverse effects such as fatigue or dizziness. If these effects occur, they may impact the ability to perform tasks requiring alertness.

Q: Can Xero be taken with vitamins or supplements?

Official regulatory documents suggest exercising caution regarding concomitant use with any substance. These documents suggest discussing all prescription and non-prescription products, including herbal and vitamin supplements, with a healthcare professional before combining them with this medicine.

Q: What happens if I miss a dose of Xero?

Regulatory documents describe the procedure for a missed dose, stating that if a dose is missed, it should be taken as soon as possible unless it is nearly time for the next scheduled dose. The regulatory instruction is to avoid taking two doses at the same time.

Q: Does Xero have a potential for dependence or withdrawal?

The active ingredient in Xero is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Due to its pharmacological class, this medicine is not associated with physical dependence or the development of withdrawal symptoms.

Q: Can Xero affect mood or behavior?

Official reports on adverse reactions state that effects on the central nervous system may occur. These can include effects such as nervousness or changes in sleep patterns.

Q: What if I take too much Xero by accident?

Official regulatory documents include a specific section detailing the signs and symptoms of an overdose. These documents consistently emphasize that emergency medical attention should be sought immediately if an overdose is suspected.

Q: Is Xero safe to use while driving?

The official document contains a specific warning that the medicine may cause side effects such as dizziness or fatigue. If these effects occur, official safety warnings advise against driving or operating machinery.

Q: Is there a chance Xero might not work for me?

Studies and official information indicate that the research evidence has certain limitations. For instance, the original study sample sizes were sometimes modest, meaning that the observed symptomatic changes may not apply to all patients in a larger, more varied population.

Q: What is the maximum recommended duration of use for Xero?

Regulatory guidelines for the short-term use of this medicine typically advise against continuous administration for longer than a specified number of days (e.g., 10 days). Official documentation specifies that continuous use beyond this period requires the explicit direction of a healthcare professional.

Q: Can Xero cause changes to vision?

Official product information lists changes to vision, such as blurred vision, as a potential adverse reaction that has been reported. Official safety information advises that visual changes should be reported to a healthcare provider.

Q: Does Xero contain common allergens like lactose or gluten?

The Summary of Product Characteristics (SmPC) and the patient information leaflet must officially list all inactive ingredients, known as excipients. This includes listing any common potential allergens such as lactose or gluten that may be present in the final product.

Q: Why is it necessary to read the official patient information leaflet for Xero?

Regulatory bodies require the patient information leaflet to provide comprehensive safety information. The leaflet includes essential details about warnings, contraindications (situations where the drug must not be used), and interaction warnings necessary for the medicine's safe and proper use.

Q: Is Xero only available by prescription?

The specific formulation and strength of Xero require a prescription from a healthcare professional. This prescription status is determined by the drug's comprehensive safety profile and the need for individualized dosing adjustments and monitoring.

Q: Does Xero cause weight changes?

Official product safety information states that potential adverse reactions associated with the medicine include changes in appetite. These changes to appetite may lead to fluctuations in body weight.

Q: Is it normal to feel a change in appetite after starting Xero?

Changes to appetite have been documented in the official safety profile as a possible adverse reaction to the medicine. Any noticeable or concerning changes in appetite should be noted and discussed with a healthcare provider.

Q: How long does Xero stay in the body after the last dose?

The elimination half-life of the active substance, which measures the time required for half the amount of the drug to be eliminated from the body, is typically documented in regulatory documents as being around 2 hours.

How should Xero be stored and disposed of?

How to Store and Dispose of Xero (Dexibuprofen)

The storage and disposal of Xero tablets must follow the official regulatory requirements to ensure product stability and safety.

Storage Conditions

Xero tablets must be stored at a temperature below 25 C (77 F), as this condition supports the drug's 2-year shelf-life. The medication should be kept in its original blister pack. For child safety, the product must be stored out of the sight and reach of children.

Disposal Instructions

Official labeling states there are no special requirements for the handling of Xero; however, the medicine must not be thrown away in wastewater or general household trash. Unused or expired tablets should be taken to a pharmacist or local collection point for proper disposal to help protect the environment.

Xero